The Drugs Controller General of India (DCGI) has approved the market authorization of India’s first quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer. The Serum Institute of India (SII) will produce this vaccine. CEO of The Serum Institute of India Adar Poonawalla tweeted the information. For the first time, an inexpensive and widely available HPV vaccination made in India will be available to treat cervical cancer in female patients. Later this year, SII hopes to launch it, and we are grateful to the DCGI, MoHFW INDIA, for their approval.
Following an assessment of the clinical trial results for the vaccine, the National Technical Advisory Group on Immunization (NTAGI) recently gave its approval to the qHPV. The Quadrivalent Human Papillomavirus (qHPV) vaccine against cervical cancer, which was produced domestically by Serum Institute of India (SII), was recommended for standard market authorization on June 15. After the vaccine’s phase 3 data were deemed to be satisfactory, suggestions were made.
Important Takeaways For All Competitive Exams:
The Food Safety and Standards Authority of India (FSSAI) has introduced the standardized vegan logo…
The Jammu & Kashmir Bank (J&K Bank) won the Gold Award at the Finacle Innovation…
The United Nations General Assembly (UNGA) has selected the five new countries to serve as…
India and the United Kingdom have jointly launched the India-UK Critical Minerals Global Supply Chain…
The Government of India has named Neelkanth Mishra as the India's next Executive Director at…
The University of Liverpool which is one of the United Kingdom's leading universities has received…